Instil Bio is a biotechnology company that develops cell therapies for solid tumor cures.
Instil Bio is a cell therapy company developing tumor infiltrating lymphocytes for the treatment of solid tumor cancers. It is advancing its proprietary manufacturing expertise, technology, and data into clinical trials, including a planned registrational study with its candidate and the first-in-human study of its next-generation engineered TIL.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 19, 2021 | IPO | $320M | — | — | — | Detail |
Dec 29, 2020 | Series C | — | 1 | — | — | Detail |
Aug 3, 2020 | Series B | $170.20M | — | — | — | Detail |
Jun 29, 2020 | Series B | $5M | — | — | — | Detail |
Mar 4, 2019 | Series A | $25M | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
HBM Healthcare Investments AG | — | Series C |